AAV8 Capsid Peptide Insertions for Liver Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors exhibit low tissue specificity and transduction efficiency for the liver, limiting their effectiveness in liver-targeted gene therapy.
Innovation Solution
Variant AAV8 capsid polypeptides with specific peptide insertions, such as those after amino acid 590, are engineered to enhance liver tropism and transduction efficiency by altering the capsid properties, allowing for targeted delivery of therapeutic genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type AAV8 vectors are used, then the vector structure is simple and easy to manufacture, but the liver-specific transduction efficiency is low
Solution Approach 1:
The patent applies local quality by making targeted peptide insertions at specific locations on the AAV8 capsid surface (e.g., positions 590, 593, or 625) rather than modifying the entire capsid structure. This localized modification approach enhances liver-specific transduction by adding liver-targeting peptides (such as GALNT14-derived peptides or other hepatotropic sequences) to specific capsid regions, thereby improving transduction efficiency without requiring complete reconstruction of the capsid architecture.
Solution Approach 2:
The patent employs composite materials by creating hybrid capsid structures that combine the native AAV8 capsid protein with exogenously added liver-targeting peptide sequences. These composite capsids integrate the advantageous properties of both components: the proven safety and packaging capacity of AAV8 combined with the liver-specific targeting capability of the inserted peptides, resulting in vectors with enhanced liver tropism while maintaining structural integrity.
2Productivity
If peptide insertions are made to enhance liver tropism, then transduction efficiency improves, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the peptide insertion sequences and their integration sites into the AAV8 capsid gene before production. The peptide sequences (such as those derived from GALNT14 or other liver-targeting motifs) are designed and validated in silico and in vitro beforehand to ensure optimal expression and proper capsid assembly. This preliminary design phase includes selecting insertion positions that minimize disruption to capsid self-assembly and stability, thereby facilitating smoother downstream manufacturing processes despite the added complexity of peptide incorporation.
3Adaptability or versatility
If the capsid structure is modified with peptide insertions, then liver specificity is enhanced, but the stability of the capsid may be affected
Solution Approach 1:
The patent applies parameter changes by carefully controlling the physical and chemical parameters of the peptide insertions, including the length of the peptide sequences (typically 5-20 amino acids), the composition of amino acids (preferring hydrophobic and aromatic residues for surface exposure), the charge distribution, and the hydrophobicity balance. These parameter optimizations ensure that the inserted peptides enhance liver specificity through improved receptor binding while maintaining capsid structural stability and proper assembly kinetics. The insertion sites are selected to avoid critical structural regions, and the peptide sequences are designed to integrate harmoniously with the native capsid protein fold.
Data Source
AI summary
The present disclosure provides variant AAV8 capsids that exhibit altered capsid properties, e.g., improved transduction efficiency and/or specificity for the liver. The present disclosure further provides nucleic acids encoding the variant AAV8 capsids, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsids, as well as host cells and compositions comprising the same. The present disclosure further provides methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.